在基因组学时代与治疗相关的骨髓质疏松症候群
Aline Renneville1, Elsa Bernard2, Jean-Baptiste Micol3
1Gustave-Roussy, Department of Medical Biology and Pathology, Villejuif, France; Gustave-Roussy, université Paris-Saclay, Inserm U1287, Villejuif, France.
Bulletin du cancer
|June 30, 2023
概括
与治疗相关的骨髓质疏松症候群 (t-MDS) 很难治疗恶性瘤. 测序方面的进步揭示了t-MDS是由遗传因素,突变和治疗引起的,导致患者的生存率低下.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
背景情况:
- 治疗相关的骨髓质疏松症候群 (t-MDS) 是一种恶性瘤,在化疗/放射治疗后发生.
- t-MDS构成了20%的骨髓质疏松症候群 (MDS),预后不佳.
- 通过深度测序技术,了解t-MDS的发病因子已经取得了进展.
研究的目的:
- 为了阐明t-MDS的多因素病原性.
- 确定导致t-MDS患者生存率低下的因素.
- 探索改善风险分层和预防策略的潜在途径.
主要方法:
- 审查了解t-MDS病原学的最新进展.
- 在t-MDS中影响患者存活时间的因素分析.
- 讨论当前的风险分层分数 (IPSS-R,IPSS-M) 以及它们对t-MDS的应用.
主要成果:
- t-MDS的发展包括生殖线易感性,体质突变,治疗压力和微环境变化.
- 低生存率与患者因素 (表现状况) 和疾病因素 (化学抵抗,TP53突变) 有关.
- 大约50%的t-MDS患者具有高/非常高的风险,而新发MDS患者的风险为30%.
结论:
- t-MDS的发病过程复杂,涉及遗传和环境相互作用.
- 新的治疗策略和改进的风险识别对于t-MDS管理至关重要.
- 需要进一步的研究来预防t-MDS并优化初级治疗策略.
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


